This site is intended for US healthcare professionals only.

    Overexpression of XPO1, a nuclear export protein, is one of the mechanisms of oncogenesis1-4

    Labelled image of XPO1 in a healthy cell
    Labelled image of XPO1 in a healthy cell

    In healthy cells:

    • XPO1 is a nuclear export protein1,2,5
    • It is responsible for carrying cargos*out of the nucleus1,2,5
    • The process is highly regulated to maintain the appropriate balance of cell growth and apoptosis3,6
    *Cargos include tumor suppressor proteins (p53, p73, FOXO3a, IκB, pRb, BRCA1), growth regulators (glucocorticoid receptors), and oncoprotein mRNA (c-Myc, cyclin D, Bcl-2, Bcl-6). The identified cargos do not represent all cargos exported by XPO1.2,3,7-10

    XPOVIO® (selinexor) is the first and only FDA-approved oral XPO1 inhibitor that gets to the cell’s core to cause cell cycle arrest and apoptosis1,2,5,11

    Annotated diagram showing XPOVIO® (selinexor) mechanism of action
    Annotated diagram showing XPOVIO® (selinexor) mechanism of action
    Rather than targeting cancer cells on their surface, such as at the B‑cell receptor, XPOVIO targets the cell at its core to inhibit XPO15,12

    References: 1. Yang J, et al. PLoS One. 2014;9(7):e102983. 2. Gupta A, et al. J Thorac Oncol. 2017;12(9):1446-1450. 3. Sun Q, et al. Signal Transduct Target Ther. 2016;1:16010. 4. Mor A, et al. Curr Opin Cell Biol. 2014;28:28-35. 5. XPOVIO (selinexor) [package insert]. Newton, MA: Karyopharm Therapeutics Inc.; June 2020. 6. Tai YT, et al. Leukemia. 2014;28(1):155-165. 7. Gravina GL, et al. J Hematol Oncol. 2014;7:85. 8. Vandevyver S, et al. Traffic. 2012;13(3):364-374. 9. Gandhi UH, et al. Clin Lymphoma Myeloma Leuk. 2018;18(5):335-345. 10. Zinkel S, et al. Cell Death Differ. 2006;13(8):1351-1359. 11. Ben-Barouch S, et al. Expert Opin Investig Drugs. 2020;29(1):15-21. 12. Chao MP. Cancer Manag Res. 2013;5:251-269.

    INDICATIONS

    • XPOVIO® (selinexor) in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
    • XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

    IMPORTANT SAFETY INFORMATION

    Thrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia was reported in patients with multiple myeloma (MM) and developed or worsened in patients with DLBCL.

    Thrombocytopenia is the leading cause of dosage modifications. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Institute platelet transfusion and/or other treatments as clinically indicated. Monitor patients for signs and symptoms of bleeding and evaluate promptly. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.